ADENOSINE A3 RECEPTOR ANTAGONISTIC AGENT AND THIAZOLE COMPOUND

Patent number: JP11193281

Publication date: 1999-07-21

Inventor: OOKAWA SHIGENORI; KIMURA HIROYUKI; KANZAKI NAOYUKI

Applicant: TAKEDA CHEMICAL INDUSTRIES LTD

Classification:

- international: ***A61K31/00; A61K31/44; A61K31/445; A61K31/535; C07D417/04; C07D417/14;*** **A61K31/00; A61K31/44; A61K31/445; A61K31/535; C07D417/00;** (IPC1-7): C07D417/04; A61K31/00; A61K31/44; A61K31/445; A61K31/535; C07D417/14

- european:

Application number: JP19980303623 19981026

Priority number(s): JP19980303623 19981026; JP19970294485 19971027

Abstract of **JP11193281**

PROBLEM TO BE SOLVED: To obtain the subject antagonistic agent having excellent adenosine A, receptor antagonistic action and high peroral absorbability and metabolic stability and useful for the prevention and treatment of asthma, inflammation, etc., by including a specific azole compound. SOLUTION: This antagonistic agent contains a 1,3-azole compound substituted with pyridyl group which may have substituents at 4 and/or 5- positions, preferably a compound of formula I (R<1> is H, a hydrocarbon group, a heterocyclic group or the like; one of R<2> and R<3> is H, pyridyl or the like and the other is pyridyl; X is S atom or the like which may be oxidized), its N-oxide or its salt. Among the compounds of formula I, the compounds of formula II (R<1a> is an aromatic heterocyclic group or the like; R<2a> is an aromatic hydrocarbon group; R<3a> is pyridyl) are new compounds producible by reacting a compound of formula III (Hal is a halogen) with a compound of formula IV. The compound of formula I is e.g. N-methyl [5-phenyl-4-(3-pyridyl)-1,3- thiazol-2-yl]amine.